These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36064438)

  • 21. Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients.
    Ahmed N; Jen SP; Altshuler D; Papadopoulos J; Pham VP; Dubrovskaya Y
    J Intensive Care Med; 2020 Aug; 35(8):763-771. PubMed ID: 29954243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
    Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
    Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Right dose, right now: using big data to optimize antibiotic dosing in the critically ill.
    Elbers PW; Girbes A; Malbrain ML; Bosman R
    Anaesthesiol Intensive Ther; 2015; 47(5):457-63. PubMed ID: 26459228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic dose optimisation in the critically ill: targets, evidence and future strategies.
    Dyer CJ; De Waele JJ; Roberts JA
    Curr Opin Crit Care; 2024 Oct; 30(5):439-447. PubMed ID: 39150038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.
    Jaruratanasirikul S; Thengyai S; Wongpoowarak W; Wattanavijitkul T; Tangkitwanitjaroen K; Sukarnjanaset W; Jullangkoon M; Samaeng M
    Antimicrob Agents Chemother; 2015; 59(6):2995-3001. PubMed ID: 25753628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients.
    Roberts JA; Choi GY; Joynt GM; Paul SK; Deans R; Peake S; Cole L; Stephens D; Bellomo R; Turnidge J; Wallis SC; Roberts MS; Roberts DM; Lassig-Smith M; Starr T; Lipman J
    BMC Infect Dis; 2016 Mar; 16():103. PubMed ID: 26932762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
    Roberts DM; Roberts JA; Roberts MS; Liu X; Nair P; Cole L; Lipman J; Bellomo R;
    Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of a loading dose of meropenem on outcomes of patients with sepsis treated by continuous renal replacement: study protocol for a randomized controlled trial.
    Ni SQ; Teng WB; Fu YH; Su W; Yang Z; Cai J; Xu JN; Deng XY; Liu XF; Fu SN; Zeng J; Zhang C
    Trials; 2022 Apr; 23(1):294. PubMed ID: 35413886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
    Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
    Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibiotic dose optimization in critically ill patients.
    Cotta MO; Roberts JA; Lipman J
    Med Intensiva; 2015 Dec; 39(9):563-72. PubMed ID: 26415688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic therapy in sepsis: No next time for a second chance!
    Shahrami B; Sharif M; Sefidani Forough A; Najmeddin F; Arabzadeh AA; Mojtahedzadeh M
    J Clin Pharm Ther; 2021 Aug; 46(4):872-876. PubMed ID: 33710622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
    Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
    Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis.
    Chai MG; Tu Q; Cotta MO; Bauer MJ; Balch R; Okafor C; Comans T; Kruger P; Meyer J; Shekar K; Brady K; Fourie C; Sharp N; Vlad L; Whiley D; Ungerer JPJ; Mcwhinney BC; Farkas A; Paterson DL; Clark JE; Hajkowicz K; Raman S; Bialasiewicz S; Lipman J; Forde BM; Harris PNA; Schlapbach LJ; Coin L; Roberts JA; Irwin AD
    Intensive Care Med; 2024 Apr; 50(4):539-547. PubMed ID: 38478027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients.
    Heffernan AJ; Sime FB; Taccone FS; Roberts JA
    Curr Opin Infect Dis; 2018 Dec; 31(6):555-565. PubMed ID: 30299354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines?
    Roberts JA; Roberts DM
    Crit Care; 2014 Jun; 18(3):156. PubMed ID: 25043141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining optimal dosing of ciprofloxacin in patients with septic shock.
    Roberts JA; Alobaid AS; Wallis SC; Perner A; Lipman J; Sjövall F
    J Antimicrob Chemother; 2019 Jun; 74(6):1662-1669. PubMed ID: 30809648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock.
    Varghese JM; Roberts JA; Lipman J
    Crit Care Clin; 2011 Jan; 27(1):19-34. PubMed ID: 21144984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?
    Heffernan AJ; Germano A; Sime FB; Roberts JA; Kimura E
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1219-1226. PubMed ID: 31154476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.